What is the role of aflibercept in the treatment of choroidal neovascularization (CNV)?

Updated: Jan 07, 2019
  • Author: Lihteh Wu, MD; Chief Editor: Andrew A Dahl, MD, FACS  more...
  • Print
Answer

The VIEW 1 and VIEW 2, two similarly designed double-masked, randomized multicenter clinical trials, demonstrated that intravitreal aflibercept dosed monthly or every 2 months after a loading dose of 3 monthly doses was noninferior to monthly ranibizumab. [46] The US Food and Drug Administration has approved aflibercept for the treatment of all angiographic subtypes of subfoveal neovascular ARMD.


Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!